Shaima Hashem

Dr. Shaima Hashem

orcid

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 November 2017 in PLOS Computational Biology
Verified
Journal Article
Open access
PDF file
SHShaima Hashem
Shaima Hashem
MTMatteo Tiberti
Matteo Tiberti
AFArianna Fornili
Arianna Fornili
New promising avenues for the pharmacological treatment of skeletal and heart muscle diseases rely on direct sarcomeric modulators, which are molecules that can directly bind to sarcomeric proteins and either inhibit or enhance their activity. A recent breakthrough has been the discovery of the myosin activator omecamtiv mecarbil (OM), which has been shown to increase the power output of the cardiac muscle and is currently in clinical trials for the treatment of heart failure. While the overall effect of OM on the mechano-chemical cycle of myosin is to increase the fraction of myosin molecules in the sarcomere that are strongly bound to actin, the molecular basis of its action is still not completely clear. We present here a Molecular Dynamics study of the motor domain of human cardiac myosin bound to OM, where the effects of the drug on the dynamical properties of the protein are investigated for the first time with atomistic resolution. We found that OM has a double effect on myosin dynamics, inducing a) an increased coupling of the motions of the converter and lever arm subdomains to the rest of the protein and b) a rewiring of the network of dynamic correlations, which produces preferential communication pathways between the OM binding site and distant functional regions. The location of the residues responsible for these effects suggests possible strategies for the future development of improved drugs and the targeting of specific cardiomyopathy-related mutations. Cardiac myosin is a motor protein responsible for the contraction of the heart muscle. New strategies for the cure of heart diseases are currently being developed by using myosin modulators, which are small molecules that can interact with myosin and modify its activity. The advantage of this approach over traditional drugs is that by directly targeting cardiac myosin it is possible to have drugs with reduced side effects. Moreover, the availability of a spectrum of molecules to finely tune myosin to a desired level of activity opens the possibility to develop more precise and personalised drug therapies. In this work, we study a recently discovered activator of cardiac myosin, omecamtiv mecarbil, in order to understand its mechanism of action. In particular, we use Molecular Dynamics simulations to unravel the effects of the drug on myosin motions, which are closely related to its function. We find that omecamtiv has a strong effect on myosin dynamics and it changes the way regions of the protein that are critical for its function interact with each other. We use these data to identify genetic mutations associated with heart diseases that could be targeted by the drug and to suggest a possible route to design drugs with different therapeutic properties.

1 December 2016 in International Journal for Parasitology: Drugs and Drug Resistance
Verified
Journal Article
Open access
MDMarion A. David
Marion A. David
SOStéphane Orlowski
Stéphane Orlowski
RPRoger K. Prichard
Roger K. Prichard
SHShaima Hashem
Shaima Hashem
FAFrançois Andre
François Andre
ALAnne Lespine
Anne Lespine
Macrocyclic lactones (ML) are important anthelmintics used in animals and humans against parasite nematodes, but their therapeutic success is compromised by the spread of ML resistance. Some ABC transporters, such as p-glycoproteins (Pgps), are selected and overexpressed in ML-resistant nematodes, supporting a role for some drug efflux proteins in ML resistance. However, the role of such proteins in ML transport remains to be clarified at the molecular level. Recently, Caenorhabditis elegans Pgp-1 (Cel-Pgp-1) has been crystallized, and its drug-modulated ATPase function characterized in vitro revealed Cel-Pgp-1 as a multidrug transporter. Using this crystal structure, we have developed an in silico drug docking model in order to study the binding of ML and other anthelmintic drugs to Cel-Pgp-1. All tested ML bound with high affinity in a unique site, within the inner chamber of the protein, supporting that ML may be transported by Cel-Pgp-1. Interestingly, interacting residues delineate a ML specific fingerprint involving H-bonds, including T1028. In particular, benzofurane and spiroketal moieties bound to specific sub-sites. When compared with the aglycone ML, such as moxidectin and ivermectin aglycone, avermectin anthelmintics have significant higher affinity for Cel-Pgp-1, likely due to the sugar substituent(s) that bind to a specific area involving H-bonds at Y771. Triclabendazole, closantel and emodepside bound with good affinities to different sub-sites in the inner chamber, partially overlapping with the ML binding site, suggesting that they could compete for Cel-Pgp-1-mediated ML transport. In conclusion, this work provides novel information on the role of nematode Pgps in transporting anthelmintics, and a valuable tool to predict drug-drug interactions and to rationally design new competitive inhibitors of clinically-relevant nematode Pgps, to improve anthelmintic therapeutics.

9 September 2021 in Chemical Science
Verified
Journal Article
Open access
PDF file
SHShaima Hashem
Shaima Hashem
VMVeronica Macaluso
Veronica Macaluso
MNMichele Nottoli
Michele Nottoli
FLFilippo Lipparini
Filippo Lipparini
LCLorenzo Cupellini
Lorenzo Cupellini
BMBenedetta Mennucci
Benedetta Mennucci
With an integrated molecular dynamics and QM/MM strategy we characterize the dark-state structure of a BLUF photoreceptor and ration alize the discrepancy between published crystal structures.

25 February 2025 in Molecules
Verified
Journal Article
Open access
PDF file
SHShaima Hashem
Shaima Hashem
ADAlexis Dougha
Alexis Dougha
Pierre TufféryPierre Tufféry
Pierre Tufféry
G-protein coupled receptors (GPCRs) are the largest family of membrane proteins engaged in transducing signals from the extracellular environment into the cell. GPCR-biased signaling occurs when two different ligands, sharing the same binding site, induce distinct signaling pathways. This selective signaling offers significant potential for the design of safer and more effective drugs. Although its molecular mechanism remains elusive, big efforts are made to try to explain this mechanism using a wide range of methods. Recent advances in computational techniques and AI technology have introduced a variety of simulations and machine learning tools that facilitate the modeling of GPCR signal transmission and the analysis of ligand-induced biased signaling. In this review, we present the current state of in silico approaches to elucidate the structural mechanism of GPCR-biased signaling. This includes molecular dynamics simulations that capture the main interactions causing the bias. We also highlight the major contributions and impacts of transmembrane domains, loops, and mutations in mediating biased signaling. Moreover, we discuss the impact of machine learning models on bias prediction and diffusion-based generative AI to design biased ligands. Ultimately, this review addresses the future directions for studying the biased signaling problem through AI approaches.

27 May 2020 in Molecular Physics
Verified
Journal Article
Closed access
SHShaima Hashem
Shaima Hashem
LCLorenzo Cupellini
Lorenzo Cupellini
FLFilippo Lipparini
Filippo Lipparini
BMBenedetta Mennucci
Benedetta Mennucci
We present a polarisable QM/MM investigation of NMR chemical shifts of a photoreceptor protein belonging to the Blue Light-Using Flavin family. Two different structures have been proposed for this photoreceptor which show a large variability in terms of the position and orientation of the protein residues around the flavin chromophore. Here, the two structures have been investigated with our multiscale approach using both DFT and MP2 level of theory. The picture that comes out comparing the 1H chemical shifts of the flavin and the most strongly interacting protein residues with the available experimental data, indicates a different behaviour of the two structures, with one showing a better correlation with NMR measurements. This shows that hybrid quantum chemical-classical simulations of NMR chemical shifts can indeed become a valuable tool to investigate the structure of complex biosystems. GRAPHICAL ABSTRACT

27 December 2018 in Angewandte Chemie
Verified
Journal Article
Open access
PDF file
MDMelissa D'Ascenzio
Melissa D'Ascenzio
KPKathryn M. Pugh
Kathryn M. Pugh
RKRebecca Konietzny
Rebecca Konietzny
GBGeorgina Berridge
Georgina Berridge
CTCynthia Tallant
Cynthia Tallant
PBPaul Brennan
Paul Brennan
Bromodomain‐containing proteins are epigenetic modulators involved in a wide range of cellular processes, from recruitment of transcription factors to pathological disruption of gene regulation and cancer development. Since the druggability of these acetyl‐lysine reader domains was established, efforts were made to develop potent and selective inhibitors across the entire family. Here we report the development of a small molecule‐based approach to covalently modify recombinant and endogenous bromodomain‐containing proteins by targeting a conserved lysine and a tyrosine residue in the variable ZA or BC loops. Moreover, the addition of a reporter tag allowed in‐gel visualization and pull‐down of the desired bromodomains.